Nextwave A Sub Of Tris Patent-Cliff Exposure & CMS Drug Spending Portfolio

Nextwave A Sub Of Tris (US): 1 reconciled FDA prescription therapies, $98.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2031-01-01
2024 CMS Total Public Spend$98.8M
2024 Medicare Part D Spend$188K
2024 Medicaid Spend$98.6M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel